Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6019556 | 1.00 | CXCR4 (0.50) | CXCR4HPGDHSD17B10KMT2AALDH1A1 | |
| SCHEMBL27568576 | 0.87 | CXCR4 (0.47) | CXCR4HPGDHSD17B10KMT2AALDH1A1 | |
| SCHEMBL6667469 | 0.87 | CXCR4 (0.47) | CXCR4HPGDHSD17B10KMT2AALDH1A1 | |
| SCHEMBL6018215 | 0.87 | CXCR4 (0.55) | CXCR4HPGDHSD17B10KMT2AALDH1A1 | |
| SCHEMBL27566493 | 0.87 | CXCR4 (0.55) | CXCR4HPGDHSD17B10KMT2AALDH1A1 | |
| SCHEMBL6018126 | 0.86 | CXCR4 (0.54) | CXCR4KMT2AALDH1A1MAPK14RAB9A | |
| SCHEMBL27616554 | 0.86 | CXCR4 (0.54) | CXCR4KMT2AALDH1A1MAPK14RAB9A | |
| SCHEMBL6018244 | 0.85 | CXCR4 (0.51) | CXCR4HPGDHSD17B10KMT2AALDH1A1 | |
| SCHEMBL6019226 | 0.84 | CXCR4 (0.51) | CXCR4HPGDHSD17B10KMT2AALDH1A1 | |
| SCHEMBL6018116 | 0.81 | CXCR4 (0.53) | CXCR4KMT2AALDH1A1MAPK14L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098215-B2 | Nitrogenous compounds and antiviral drugs containing the same | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20040092556-A1 | Nitrogenous compounds and antiviral drugs containing the same | KUREHA CORPORATION (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1273571-A1 | NITROGENOUS COMPOUNDS AND ANTIVIRAL DRUGS CONTAINING THE SAME | Kureha Chemical Industry Co., Ltd. (JP) | 2003-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092556-A1 | Nitrogenous compounds and antiviral drugs containing the same | NSUN2, ZC3HAV1L, PNP | CXCR4 2185/4885HPGD 2047/4885HSD17B10 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.